# US 2015/0031725 A1 · Compositions and methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031725 A1
- Document ID: US20150031725A1
- Status: Published application
- Kind: A1
- Application number: 14/505,288
- Filed: 2014-10-02
- Published: 2015-01-29
- Earliest claimed: 2012-04-02
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Richard J. Pietras; Michael E. Jung; Diana C. Marquez-Garban; Gang Deng
- Web page: https://patentgrep.com/patent/US20150031725A1

## CPC

- C07D 493/04: Ortho-condensed systems
- A61K 31/365: Lactones
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula selected from the group consisting of:
wherein,
L0 is independently a bond or an unsubstituted C1-C10 alkylene; and
R1 and R2 are independently hydrogen, —OH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; where R1 and R2 may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or a substituted or unsubstituted heteroaryl; with the proviso that the compound, or the pharmaceutically acceptable salt thereof is not

### Claim 2 (depends on 1)

The compound, or a pharmaceutically acceptable salt thereof, of claim 1, wherein the compound has a formula selected from the group consisting of:

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is L1-R3;
L0 is independently a bond or an unsubstituted C1-C10 alkylene; and
R3 is independently hydrogen, halogen, —CH3, —CF3, —CCl3, —CN, —S(O)CH3, —OH, —NH2, —COOH, —CONH2, —NO2, —C(O)CH3, —CH2CH3, —CH2CH2OH, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC═(O)NHNH2, —NHC═(O)NH2, —NHSO2H, —NHC═(O)H, —NHC(O)OH, —NHOH, —OCH3, —OCF3, —OCHF2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R3 is independently hydrogen, halogen, —CH3, —CF3, —CCl3, —CN, —S(O)CH3, —OH, —NH2, —COOH, —CONH2, —NO2, —C(O)CH3, —CH2CH3, —CH2CH2OH, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC═(O)NHNH2, —NHC═(O)NH2, —NHSO2H, —NHC═(O)H, —NHC(O)OH, —NHOH, —OCH3, —OCF3, —OCHF2, 4-methoxybenzyl, 4-methoxyphenyl, or pyridyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is L2-R4;
L2 is independently a bond or an unsubstituted C1-C10 alkylene; and
R4 is independently hydrogen, halogen, —CH3, —CF3, —CCl3, —CN, —S(O)CH3, —OH, —NH2, —COOH, —CONH2, —NO2, —C(O)CH3, —CH2CH3, —CH2CH2OH, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC═(O)NHNH2, —NHC═(O)NH2, —NHSO2H, —NHC═(O)H, —NHC(O)OH, —NHOH, —OCH3, —OCF3, —OCHF2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R4 is independently hydrogen, halogen, —CH3, —CF3, —CCl3, —CN, —S(O)CH3, —OH, —NH2, —COOH, —CONH2, —NO2, —C(O)CH3, —CH2CH3, —CH2CH2OH, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC═(O)NHNH2, —NHC═(O)NH2, —NHSO2H, —NHC═(O)H, —NHC(O)OH, —NHOH, —OCH3, —OCF3, —OCHF2, 4-methoxybenzyl, 4-methoxyphenyl, or pyridyl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are joined to form an unsubstituted heterocycloalkyl.

### Claim 8 (depends on 1)

The compound, or a pharmaceutically acceptable salt thereof, of claim 1, wherein the compound is selected from the group consisting of

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, comprising a second agent wherein said second agent is an anti-cancer agent.

### Claim 11 (depends on 1)

A method of treating cancer in a patient in need of said treatment, said method comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to said patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein said cancer is breast cancer.

### Claim 13 (depends on 12)

The method of claim 12, wherein said breast cancer is resistant to an anti-cancer agent.

### Claim 14 (depends on 11)

The method of claim 11, wherein said cancer is lung cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein said lung cancer is resistant to an anti-cancer agent.

### Claim 16 (depends on 1)

A method of treating a non-malignant hyperproliferative disease in a patient in need of said treatment, said method comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to said patient.

### Claim 17 (depends on 1)

A method of inhibiting cancer cell growth or survival comprising contacting the cell with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said cancer cell is a cancer stem cell.

### Claim 19 (depends on 1)

A method of decreasing the level of activity of NF-κB or mTOR in a cell comprising contacting the cell with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A method of increasing the level of activity of TSC1 or TSC2 in a cell comprising contacting the cell with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
